• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

A year in review: Dermatology Times coverage in 2019

Slideshow

In this slideshow, review the advancements, changes and trends that shaped dermatology in 2019.

In this slideshow, review the advancements, changes and trends that shaped dermatology in 2019.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report

April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report

Article
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Podcast
Definitions and Diagnostic Criteria of Generalized Pustular Psoriasis Require Continuity, Accuracy, Researchers Report

Definitions and Diagnostic Criteria of Generalized Pustular Psoriasis Require Continuity, Accuracy, Researchers Report

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Finger-to-Palm Distance Among Potential Indicators of Skin Thickening, Early-Onset Systemic Sclerosis

Finger-to-Palm Distance Among Potential Indicators of Skin Thickening, Early-Onset Systemic Sclerosis

Article
BD2-Selective BET Inhibitor VYN202 Demonstrates Positive Safety and Tolerability in Phase 1a Trial

BD2-Selective BET Inhibitor VYN202 Demonstrates Positive Safety and Tolerability in Phase 1a Trial

Article
© 2024 MJH Life Sciences

All rights reserved.